Roth MKM Reaffirms Their Buy Rating on HeartBeam (BEAT)
Roth MKM analyst Kyle Bauser reiterated a Buy rating on HeartBeam today and set a price target of $4.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Bauser covers the Healthcare sector, focusing on stocks such as Sanuwave Health, HeartBeam, and Electromed. According to TipRanks, Bauser has an average return of -11.9% and a 38.03% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for HeartBeam with a $4.83 average price target.
Based on HeartBeam’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.26 million. In comparison, last year the company had a GAAP net loss of $4.98 million
Read More on BEAT:
Disclaimer & DisclosureReport an Issue
- HeartBeam (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal
- Why Is HeartBeam Stock (BEAT) Up Today?
- HeartBeam announces FDA clearance for 12-lead ECG synthesis software
- HeartBeam initiated with a Buy at H.C. Wainwright
- HeartBeam (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.